26565 Extended Gastrointestinal Panel, NAT

Campylobacter species (C. jejuni/coli/upsaliensis), Plesiomonas shigelloides, Vibrio cholera, Enteroaggregative Escherichia coli (EAEC), Enteropathogenic Escherichia coli (EPEC), Enterotoxigenic Escherichia coli (ETEC), Shiga toxin producing E. coli, Escherichia coli O157, Shigella/Enteroinvasive Escherichia coli (EIEC), Cyclospora cayetanensis, Giardia, Astrovirus, Norovirus GI/GII, Rotavirus A, Gastrointestinal Infections, Cryptosporidium species, Entamoeba histolytica, Sapovirus, Salmonella species, Yersinia species, Vibrio species, Adenovirus F 40/41, Gastrointestinal Pathogen Panel PCR, Stool, Feces, Nucleic Acid Test, Enteric Pathogen​

​The extended GI pathogen panel is a multiplex PCR assay for the detection of multiple bacterial, viral and parasite targets specifically:

-Campylobacter species (Campylobacter jejuni/Campylobacter coli/Campylobacter upsaliensis)

-Plesiomonas shigelloides

-Salmonella species

-Vibrio species (Vibrio parahaemolyticus, Vibrio vulnificus, Vibrio cholerae)

-Vibrio cholerae-Yersinia species

-Enteroaggregative Escherichia coli (EAEC)

-Enteropathogenic E coli (EPEC)

-Enterotoxigenic E coli (ETEC)

-Shiga toxin

-E coli O157

-Shigella/Enteroinvasive E coli (EIEC)

-Cryptosporidium species

-Cyclospora cayetanensis

-Entamoeba histolytica

-Giardia

-Adenovirus F 40/41

-Astrovirus

-Norovirus GI/GII

-Rotavirus A

-Sapovirus

Acute diarrhea occurring after 3 days of hospitalization is unlikely to be due to bacterial enteropathogens.  Consider a Clostridium difficile toxin nucleic acid assay for C. difficile-associated nosocomial diarrhea. (See Clostridium difficile Toxin Nucleic Acid).

Specified positive stool samples are forwarded to the Wisconsin State Lab of Hygiene (WSLH) for surveillance testing. STEC positive samples will be tested to differentiate stx1 and stx2 and subtyped against that most common serogroups in the US.  Salmonella serotyping is also performed. Surveillance data are generated for public health purposes and are not reported to the medical record unless otherwise requested by Provider.

​​NOTE - the preferred specimen container is raw stool in a leak-proof container.

If submitting in Cary-Blair, remove cap and place approximately 1 gram of the raw stool into the transport medium or a sufficient amount to bring the liquid level up to the "fill to here" line.

​Feces, Liquid or Soft Raw Stool

​Any inhibition of amplification will be detected through the use of an internal amplification control.​

​A negative result should not rule-out infection in patients with a high pretest probability for gastrointestinal infection. The assay does not test for all potential infectious agents of diarrheal disease.
Positive results do not distinguish between a viable or replicating organism and the presence of a nonviable organism or nucleic acid, nor do they exclude the potential for coinfection by organisms not contained within the panel.
Results of the panel are intended to aid in the diagnosis of illness and are meant to be used in conjunction with other clinical and epidemiological findings. This GI panel should not be used as a test of cure.